Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?Journal of the American College of Cardiology, 2015-06, Vol.65 (24), p.2638-2651 [Peer Reviewed Journal]American College of Cardiology Foundation ;2015 American College of Cardiology Foundation ;Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 23, 2015 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2015.05.001 ;PMID: 26088304Full text available |
|
2 |
Material Type: Article
|
The P-Glycoprotein Transport System and Cardiovascular DrugsJournal of the American College of Cardiology, 2013-06, Vol.61 (25), p.2495-2502 [Peer Reviewed Journal]American College of Cardiology Foundation ;2013 American College of Cardiology Foundation ;2014 INIST-CNRS ;Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 25, 2013 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2013.02.058 ;PMID: 23563132 ;CODEN: JACCDIFull text available |
|
3 |
Material Type: Article
|
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsThe New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1500858 ;PMID: 25773607Full text available |
|
4 |
Material Type: Article
|
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet (British edition), 2014-03, Vol.383 (9921), p.955-962 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 15, 2014 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)62343-0 ;PMID: 24315724 ;CODEN: LANCAOFull text available |
|
5 |
Material Type: Article
|
Cognitive Function in a Randomized Trial of EvolocumabThe New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214Full text available |
|
6 |
Material Type: Article
|
Inflammatory and Cholesterol Risk in the FOURIER TrialCirculation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2018 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034032 ;PMID: 29530884Full text available |
|
7 |
Material Type: Article
|
Atherothrombotic Risk Stratification and Ezetimibe for Secondary PreventionJournal of the American College of Cardiology, 2017-02, Vol.69 (8), p.911-921 [Peer Reviewed Journal]American College of Cardiology Foundation ;2017 American College of Cardiology Foundation ;Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Feb 28, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.11.070 ;PMID: 28231942Full text available |
|
8 |
Material Type: Article
|
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart DiseaseJournal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1363-1371 [Peer Reviewed Journal]The Authors ;2017 The Authors ;Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 21, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.12.038 ;PMID: 28302287Full text available |
|
9 |
Material Type: Article
|
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialThe Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 6, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61943-7 ;PMID: 25769361 ;CODEN: LANCAOFull text available |
|
10 |
Material Type: Article
|
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialJournal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970 [Peer Reviewed Journal]Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;2019. American College of Cardiology Foundation ;ISSN: 0735-1097 ;ISSN: 1558-3597 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.03.513 ;PMID: 31196453Full text available |
|
11 |
Material Type: Article
|
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 TrialJournal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1372-1382 [Peer Reviewed Journal]The Authors ;2017 The Authors ;Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 21, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.12.031 ;PMID: 28302288Full text available |
|
12 |
Material Type: Article
|
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AFJournal of the American College of Cardiology, 2016-06, Vol.67 (24), p.2888-2899 [Peer Reviewed Journal]American College of Cardiology Foundation ;2016 American College of Cardiology Foundation ;Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 21, 2016 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.02.082 ;PMID: 27311528Full text available |
|
13 |
Material Type: Article
|
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096 [Peer Reviewed Journal]2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. 2016 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.P065334 ;PMID: 27102113Full text available |
|
14 |
Material Type: Article
|
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialThe American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601Full text available |
|
15 |
Material Type: Article
|
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 TrialJournal of the American Heart Association, 2016-05, Vol.5 (5), p.n/a [Peer Reviewed Journal]2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/JAHA.116.003432 ;PMID: 27207971Full text available |
|
16 |
Material Type: Article
|
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288 [Peer Reviewed Journal]American College of Cardiology Foundation ;2014 American College of Cardiology Foundation ;Copyright Elsevier Limited Apr 8, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2014.01.006Full text available |
|
17 |
Material Type: Article
|
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyThe Lancet (British edition), 2012-12, Vol.380 (9858), p.2007-2017 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61770-X ;PMID: 23141813 ;CODEN: LANCAOFull text available |
|
18 |
Material Type: Article
|
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48European heart journal, 2014-06, Vol.35 (22), p.1457-1465 [Peer Reviewed Journal]Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com. ;Distributed under a Creative Commons Attribution 4.0 International License ;Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com. 2013 ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/eht500 ;PMID: 24302269Full text available |
|
19 |
Material Type: Article
|
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous ThromboembolismCirculation (New York, N.Y.), 2020-05, Vol.141 (20), p.1600-1607 [Peer Reviewed Journal]2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.120.046397 ;PMID: 32223429Full text available |
|
20 |
Material Type: Article
|
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)The American heart journal, 2010-10, Vol.160 (4), p.635-641.e2 [Peer Reviewed Journal]Mosby, Inc. ;2010 Mosby, Inc. ;2015 INIST-CNRS ;Copyright © 2010 Mosby, Inc. All rights reserved. ;Copyright Elsevier Limited Oct 2010 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2010.06.042 ;PMID: 20934556 ;CODEN: AHJOA2Full text available |